Independent site, not affiliated with the journal Reproduction, its publishers or the Society for Reproduction and Fertility. About this site

Home › Explained › Fertility and IVF explained

Fertility and IVF explained

Ovarian hyperstimulation syndrome (OHSS) explained: who is at risk, the warning signs and how clinics prevent it

Most people who have IVF never experience more than some bloating after egg collection. A small number react so strongly to the stimulation drugs that their ovaries swell and fluid leaks out of the blood vessels. This is ovarian hyperstimulation syndrome. Here is how common it is, how to recognise it, and how modern protocols have made the severe form largely preventable.

By the reproduction-online.org editorial team · Published 20 November 2026 · Sources checked 20 November 2026 · 6 min read

A scientist pipetting samples in a laboratory
Illustrative photo: Scientist pipetting samples of bronchoalveolar, Centers for Disease Control and Prevention, CC0 via Rawpixel. Credits

What OHSS is

In an IVF cycle, daily injections of follicle-stimulating hormone (gonadotrophins) are used to make several eggs mature at once, rather than the single egg of a natural cycle. Ovarian hyperstimulation syndrome (OHSS) is an excessive response to those drugs. The Human Fertilisation and Embryology Authority (HFEA) describes it as a reaction in people who are very sensitive to the medication, so that too many eggs develop and the ovaries become very large and painful (HFEA, Risks of fertility treatment).

The Royal College of Obstetricians and Gynaecologists (RCOG) explains the mechanism in its patient leaflet: overstimulated ovaries enlarge and release substances into the bloodstream that make blood vessels leaky. Fluid passes into the abdomen and, in severe cases, into the space around the lungs and heart. The kidneys, liver and lungs can be affected, and a very small number of deaths have been reported.

The trigger matters. The final injection that ripens the eggs before collection has traditionally been human chorionic gonadotrophin (hCG), a hormone that keeps acting on the ovaries for days. A pregnancy produces hCG too, which is why OHSS can flare up again, or last longer, if the cycle results in a pregnancy.

How common it is

The figures depend on which form of OHSS is counted:

  • Mild OHSS is common. Both the HFEA and the RCOG say it affects around a third of women having IVF, and it can usually be managed at home with pain relief.
  • Moderate or severe OHSS is much less frequent. The RCOG puts it at just over 1 in 100 women; the patient version of the European Society of Human Reproduction and Embryology (ESHRE) guideline on ovarian stimulation says severe OHSS occurs in about 1 to 2% of IVF cycles.

The two estimates are not contradictory: one counts women, the other cycles. Both say the same thing: discomfort is frequent, serious illness is uncommon.

Who is at higher risk

According to the RCOG, the risk is higher in women who have polycystic ovaries, are under 30, have had OHSS before, or become pregnant in the same cycle, particularly with twins or more.

Clinics also look at the response during the cycle itself. ESHRE suggests defining a high response as more than 18 follicles of at least 11 mm on the day of the trigger, or 18 or more eggs collected, a level associated with an increased risk of OHSS. More eggs do not mean better chances beyond a point: the ESHRE patient leaflet notes that around 8 to 15 eggs is often optimal and that very high numbers do not further increase the chance of a live birth. Why the number of eggs is only one part of the picture is explained in IVF success rates explained.

The warning signs

The HFEA lists the symptoms to report: a swollen stomach and stomach pain, which can be severe; nausea and vomiting; shortness of breath; feeling faint; and passing less urine than usual. Strong symptoms generally appear in the week after egg collection.

The RCOG describes three levels:

  • Mild: some abdominal swelling, discomfort and nausea.
  • Moderate: worse swelling because fluid has built up in the abdomen, with pain and vomiting.
  • Severe: in addition, extreme thirst and dehydration, small amounts of dark urine, or difficulty breathing because of fluid in the chest. A swollen, tender leg or chest pain with breathlessness may signal a blood clot.

The NHS advises people having IVF to call 999 or go to A&E if they have difficulty breathing, pain in the chest or upper back, or are very thirsty and passing less urine than usual, as these can be signs of severe OHSS. Some of the same symptoms, notably one-sided lower abdominal pain and pain in the tip of the shoulder, can also point to an ectopic pregnancy, which is another reason not to wait. A clinic should give every patient a 24-hour contact number; the HFEA's advice is to call it and never to feel you are wasting its time.

How it is treated

There is no treatment that reverses OHSS. It resolves with time, and care aims to relieve symptoms and prevent complications. According to the RCOG:

  • mild OHSS is managed at home with regular drinks according to thirst, paracetamol or codeine for pain, and staying active to reduce the risk of a clot; anti-inflammatory drugs such as ibuprofen and aspirin should be avoided because they can affect the kidneys;
  • in hospital, doctors monitor urine output, weight, waist size, blood tests and ultrasound, and may give anti-sickness drugs and fluids through a drip;
  • support stockings and heparin injections are used to prevent thrombosis, continued for seven days after symptoms resolve, or until the end of the 12th week if the woman is pregnant;
  • if the abdomen is tense with fluid, a thin needle or tube can be inserted under ultrasound guidance to drain it (paracentesis), which eases discomfort and helps breathing and kidney function.

Most symptoms settle within 7 to 10 days. Without a pregnancy, OHSS usually improves by the next period; with a pregnancy it can last several weeks. The RCOG adds that women who had OHSS and become pregnant may have a higher risk of pre-eclampsia and preterm birth, but that there are no known risks to the baby's development from OHSS itself.

How clinics prevent it

NICE's 2026 fertility guideline (NG257) does not set out its own prevention protocol. It refers clinicians to part G of the ESHRE guideline on ovarian stimulation for IVF/ICSI (2025 update), and keeps one recommendation of its own: clinics providing stimulation with gonadotrophins should have protocols in place for preventing, diagnosing and managing OHSS (NICE NG257, section 1.46).

The ESHRE guideline (ESHRE, Guideline on ovarian stimulation for IVF/ICSI) combines several measures:

  • Assess the risk first. Before stimulation, a risk assessment for a high response is advised, to tailor the protocol, the dose, the trigger and the embryo transfer strategy.
  • Use the antagonist protocol and a lower dose. The GnRH antagonist ("short") protocol is recommended over agonist protocols, with comparable efficacy and higher safety, and is recommended for predicted high responders. A reduced gonadotrophin dose (100 to under 150 IU) is probably recommended for them.
  • Change the trigger. In women at risk, a GnRH agonist trigger is recommended instead of hCG for final egg maturation. It produces a short natural surge of hormones and does not keep stimulating the ovaries the way hCG does. It is preferred over "coasting", the older practice of pausing the injections. Adding hCG to the agonist as a "dual trigger" is not recommended for high responders.
  • Freeze all embryos. Combined with the agonist trigger, a freeze-all strategy is recommended to minimise severe OHSS: no fresh transfer means no pregnancy hCG in that cycle, which removes the cause of late-onset OHSS. The embryos are transferred later, in a frozen cycle. If a clinic used hCG in an agonist protocol for a high responder, freezing all embryos is recommended for the same reason.
  • Medication after collection. Dopamine agonists, such as cabergoline, are recommended to reduce the risk of early OHSS, particularly when hCG was used as the trigger.
  • Cancel only in extreme cases. Cancelling the cycle is rarely necessary because the other measures work well; the patient leaflet reserves it for extremely high responses, for example more than 25 to 30 follicles.

ESHRE's conclusion for patients is that with these strategies most cases of severe OHSS can be prevented. The same approach is used for egg freezing, where no fresh transfer is planned anyway; our guide to egg freezing covers the numbers of eggs usually aimed for.

Questions to ask before stimulation

  • Based on my AMH, follicle count and history, am I likely to have a high response, and how will my dose be adjusted?
  • Will you use an antagonist protocol and, if my response is high, an agonist trigger with all embryos frozen?
  • What is the clinic's written protocol for OHSS, and who do I call at night or at the weekend?
  • Are any extra treatments being proposed during stimulation, and on what evidence? Our review of IVF add-ons summarises what the regulator says about them.

This article summarises HFEA, NHS and RCOG patient information, NICE guidance and the ESHRE guideline as available on 20 November 2026. It is not personal medical advice. If you have symptoms after fertility treatment, contact your clinic or, in an emergency, call 999.

Sources

  1. HFEA, Risks of fertility treatment (section on ovarian hyperstimulation syndrome)
  2. NICE, Fertility problems: assessment and treatment (NG257), 31 March 2026, section 1.46 Preventing OHSS
  3. ESHRE, Guideline on ovarian stimulation for IVF/ICSI (2025 update), part G Prevention of OHSS, pocket guideline and patient version; summary paper in Human Reproduction (doi:10.1093/humrep/deag018)
  4. Royal College of Obstetricians and Gynaecologists, Ovarian hyperstimulation syndrome (OHSS), patient information based on Green-top Guideline No. 5
  5. NHS, IVF: risks

Data are those published by the sources on the dates shown. If you spot an error, tell us; corrections are made in place with a dated note.